期刊文献+

阿司匹林抵抗的实验相关研究 被引量:2

A laboratory research of aspirin resistance
下载PDF
导出
摘要 目的比较不同血小板功能检测方法对阿司匹林疗效判断及其临床应用价值。方法采用血小板功能分析仪-100(platelet function analyzer,PFA-100)和光学法,应用不同的诱导剂(花生四烯酸、二磷腺苷酸、肾上腺素和胶原)测定血小板聚集率,分别对40例正常人、51例原发性高血压未服用阿司匹林患者及54例原发性高血压服用阿司匹林(100 mg/d)患者进行血小板功能测定,并以P-选择素水平的检测结果为对照,分析2种方法检测结果。结果原发性高血压服用阿司匹林组(服药组)中4种诱导剂测得的光学法血小板聚集率较正常组和临床对照组均明显下降(P均<0.05);服药组中PFA-100 CEPI测得的闭合时间(CT)值较正常组和临床对照组显著延长(P<0.01)。光学法血小板聚集检测的AR组及PFA-100测得的PFA-AR组中P-选择素的水平均显著增高。PFA-100对AR检出的敏感度较光学法血小板聚集高。PFA-100 CEPI检测盒与临床事件的一致性较光学法血小板聚集高。结论光学法血小板聚集检测阿司匹林疗效,以AA作为诱导剂更敏感、特异;使用不同诱导剂进行监测有助于对更全面了解阿司匹林疗效;PFA-100较传统光学法血小板聚集有更好的敏感性,与临床事件的一致性高。 Objective To measure the clinical effieacy of aspirin between different test of platelet function. Methods To measure the platelet function by using PFA-100 and optical aggregonletry by four reducer among 40 normal persons, 51 primary hypertension patients without taking aspirin and 54 primary hypertension patients taking aspirin 100 mg/d and analyse the agreemence between two methods by contrast with P-seleetin level. Results The platelet aggregometry reduced by AA, ADP, EPI and COL were significandy decreased than the normal group and clinical control group( P 〈 0.05) ;PFA-100 CEPI CTs in medication group were significandy longer than the normal group and clinical control group( P 〈 0. 01 ). The P-seletin level of AR detecting by two methods were both significant higher. The sensitivity of PFA-100 is higher than optical platelet aggregometry. The consistency between PFA-100 CEPI cartridge vs clinical events was higher than that between optical platelet aggregometry vs clinical events. Conclusion AA is the most sensitive reducer in optical platelet function measuring aspirin effcity. PFA-100 is another both sensitive and convenient method in measuring the platelet function in aspirin-taking persons.
出处 《中国实验诊断学》 北大核心 2009年第9期1179-1182,共4页 Chinese Journal of Laboratory Diagnosis
基金 上海市科委基金(074119601)
关键词 阿司匹林抵抗 PFA-100 光学法血小板聚集 P-选择素 aspirin Resistance optical platelet aggregometry PFA- 100 P-selectin
  • 相关文献

参考文献12

  • 1Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence og aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001,88(3) : 230.
  • 2Isabel Coma-Canella, Amelia Velasco, Sara Castano. Prevalence of aspirin resistance measured by PFA-100[J]. Int J Cardiol,2005,101:71.
  • 3Christoph JK, Guido KS, Helmut Get al. Duration of effects of aspirin on platelet function in healthy volunteers: an analysis using the PFA-100[J]. Jour of Cli Anes,2006,18:12.
  • 4James ED. Aspirin Resistance: Is it Real? Is it Clinically Significant[ J]? Am J Med,2007,120: 1.
  • 5Sane DC, McKee SA, Malinin AI, et al. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin[J]. Am J Cardiol,2002,90:893.
  • 6Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphat[J]. Thromb Res, 2002,107 : 45.
  • 7Bomal C, Lazarowski E, van Heusden C, et al. Resistance to aspirin si increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate[ J ]. Thromb J, 2005,3 : 1186.
  • 8Blake GJ, Ridker PM. Novel clinical markers of vascular wall in flammation [ J ]. Circ Res, 2001,89: 763.
  • 9Alexandre LG, Garrett P, Norma S, et al. Inhibition of platelet GP Ⅱ b- Ⅲ a and P-selectin expression by aspirin is impaired by stress hyperglycemia [ J ]. Jour of Diab and its Compli, 2008,23 ( 1 ) : 65.
  • 10Tsantes AE, et al, Monitoring aspirin treatment in patients with thrombocytosis: Comparison of file platelet function analyzer (PFA)-100 with optical aggregometry[ J ]. Thromb Res, 2008,123 ( 1 ) : 100.

二级参考文献7

  • 1[1]Antithrombotic Trialists'Collaboration.Collaborative meta-analysis of randomised trials of antiphtelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324:71-86.
  • 2[2]Yusuf S,Zhao F,Mehta SR,et al.Effectsof clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation[J].N Engl J Med,2001,345:494-502.
  • 3[3]Gum PA,Kottke-Marchant K,Poggio ED,et al.Pro-file and prevalence of aspirin resistance in patients with cardiovascular disease[J].Am J Cardiol,2001,88:230.
  • 4[4]Helgason CM,Bolin KM,Hoff JA,et al.Development of aspirin resistance in persons with previous ischemic stroke[J].Stroke,1994,25;2331-2336.
  • 5[5]Westerbacka J,Y Ki-jarvinen H,Turpeinen A,et al.Inhbition of platelet collagen interaction anin vivo action of insulin abolished by insulin resistance in obosity[J].Arterioscler Thromb Vasc Biol,2002,22(2):167-172.
  • 6[6]Hung J,Lam JYT,Lacoste L,et al.Cigarettesmoking acutely increases platelet thrombusformation in patients with coronary arterydisease taking aspirin[J].Circulation,1995,92:2432-2436.
  • 7[7]Blake GJ,Ridker PM.Novel clinical markers of vascular wall in flammation[J].Citc Res,2001,89:763-771.

共引文献4

同被引文献28

  • 1Falck-Ytter Y ,Francis CW ,Johanson NA ,et al. Prevention of VET in or- thopedic surgery patients:Antithrombotic Therapy and Prevention of Throm- bosis,9th ed:American College of Chest Physicians Evidence-Based Cli- nical Practice Guidelines[J]. Chest, 2012,141 (2 Suppl) : e278S-325S.
  • 2Vlachojannis GJ, Dimitropoulos G, Alexopoulos D. Clopidogrel resistance: current aspects and future directions[J]. Hellenic J Cardiol, 2011,52 (3) : 236-245.
  • 3Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans[J]. Chest, 2006,129 (3) : 734-737.
  • 4Nuttall GA, Brown MJ,Stombaugh JW,et al. Time and cardiac risk of sur-gery afterbare-metalstentper cutaneouscoronary intervention [J]. Anesthe- siology, 2008,109 ( 4 ) : 588-595.
  • 5Kristensen SD, Knuuti J,Saraste A,et al. 2014 ESC/ESA Guidelineson non-cardiac surgery:cardiovascular assessment and management:The Joint Task Force on non-cardiac surgery:cardiovascularassessment and mana- gement of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)[J]. Eur Heart J,2014,35(35) :2383-2431.
  • 6Breet NJ,Van Werkum JW, Bouman H J, et al. Comparison of platelet func- tion tests in predicting clinical outcome in patients undergoing coronary stent implantation[J]. JAMA, 2010,303 (8) : 754-762.
  • 7Gonzalez E, Kashuk L, Moore EE, et al. Differentiation ofenzymatic from platelet hypercoagulability using the novel thrombelastography parameter delta[J]. J Surg Res, 2010,163 ( 1 ) :96-101.
  • 8Gurbel PA ,Bliden KP,Navickas IA ,et al. Adenosine diphosphate induced platelet-fibrin clot strength:a new thrombelastographicindicator of long- term poststenting ischemic events[J]. Am Heart J, 2010,160 (2) : 346-354.
  • 9Gonzalez E, Kashuk L, Moore EE, et al. Differentiation ofenzymatic from platelet hypercoagulability using the novel thrombelastography parameter delta[J]. J Surg Res, 2010,163 ( 1 ) : 96-101.
  • 10De Cuyper IM, Meinders M,Van De Vijver E, et al. A novel flow cytometry- based platelet aggregation assay[J]. Blood, 2013,121 ( 10 ) : e70-e80.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部